Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Dec;155(7):1085-92.
doi: 10.1038/bjp.2008.369. Epub 2008 Sep 22.

Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease

O Grip  1 , S Janciauskiene, A Bredberg
Affiliations
Clinical Trial

Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease

O Grip et al. Br J Pharmacol. 2008 Dec.

Abstract

Background and purpose: Experimental and clinical investigations have revealed that statins can downregulate both acute and chronic inflammatory processes. Whether statins express anti-inflammatory activities in the treatment of Crohn's disease is unknown.

Experimental approach: Ten patients were given 80 mg atorvastatin once daily for 13 weeks and then followed up for 8 weeks after the treatment. The anti-inflammatory effects of statin were assessed by measuring levels of plasma C-reactive protein (CRP), soluble (s) CD14, tumour necrosis factor (TNF)-alpha, sTNFRI and II, CCL2 and 8 and the mucosal inflammation by faecal calprotectin. Circulating monocytes were subgrouped and their chemokine receptor expression of CCR2 and CX(3)CR1 were analysed.

Key results: In 8 of 10 patients, atorvastatin treatment reduced CRP (P=0.008) and sTNFRII (P=0.064). A slight decrease in plasma levels of sCD14, TNF-alpha and sTNFRI was observed in 7/10 patients and faecal calprotectin was reduced in 8/10 patients. We also observed that the treatment diminished expression of CCR2 and CX(3)CR1 on monocyte populations (P=0.014). At the follow-up visit, 8 weeks after the atorvastatin treatment was terminated, CRP levels had returned to those seen before the treatment.

Conclusions and implications: Our findings imply that atorvastatin therapy reduces inflammation in patients with Crohn's disease and, therefore, encourage further investigations of statin-mediated protective effects in inflammatory bowel diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
C-reactive protein (CRP) levels of 10 patients receiving 80 mg atorvastatin once daily for 13 weeks (grey area) and then followed up 8 weeks after the termination of treatment.
Figure 2
Figure 2
Peripheral monocytes analysed by flow cytometry. Leukocytes initially separated in bivariate plot of forward scatter (FSC) vs side scatter (SSC) to identify monocytes and ellipse gated in R1. Then gated monocytes were subdivided by expression of CD14, CD16 and CD56. Subpopulations are defined as CD14highCD16−, region 2; CD14highCD16+, region 3; CD14lowCD16+, region 5 and CD14+CD56+, region 9.
Figure 3
Figure 3
Crohn's disease activity index (CDAI) of 10 patients receiving 80 mg atorvastatin once daily for 13 weeks (grey area) and then followed up 8 weeks after the termination of treatment.
See this image and copyright information in PMC

References

    1. Arias MA, Rey Nores JE, Vita N, Stelter F, Borysiewicz LK, Ferrara P, et al. Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol. 2000;164:3480–3486. - PubMed
    1. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol. 2003;199:28–35. - PubMed
    1. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol. 2004;172:4470–4479. - PubMed
    1. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol. 2000;35:64–69. - PubMed
    1. Best WR, Becktel JM, Singleton JW, Kern F., Jr Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439–444. - PubMed

Publication types

MeSH terms